

## Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

Afua A. Mensah,<sup>1\*</sup> Luciano Cascione,<sup>1,2,3\*</sup> Eugenio Gaudio,<sup>1</sup> Chiara Tarantelli,<sup>1</sup> Riccardo Bomben,<sup>4</sup> Elena Bernasconi,<sup>1</sup> Domenico Zito,<sup>5,6</sup> Andrea Lampis,<sup>5,6</sup> Jens C. Hahne,<sup>5,6</sup> Andrea Rinaldi,<sup>1</sup> Anastasios Stathis,<sup>3</sup> Emanuele Zucca,<sup>3</sup> Ivo Kwee,<sup>1,2,7</sup> Valter Gattei,<sup>4</sup> Nicola Valeri,<sup>5,6</sup> Maria E Riveiro<sup>8</sup> and Francesco Bertoni<sup>1</sup>

<sup>1</sup>Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland; <sup>2</sup>Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland; <sup>3</sup>Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; <sup>4</sup>Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Aviano, Italy; <sup>5</sup>The Institute of Cancer Research, London, UK; <sup>6</sup>The Royal Marsden NHS Foundation Trust, London and Surrey, UK; <sup>7</sup>Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland and <sup>8</sup>Oncology Therapeutic Development, Clichy, France.

*\*These authors contributed equally to this work.*

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.191684

Received: February 20, 2018.


Accepted: July 31, 2018.

Pre-published: August 3, 2018.

Correspondence: frbertoni@mac.com

---

## Supplementary Data



### Supplementary Figure 1

OTX015 modulates miRNA expression in an *in vivo* DLBCL model. miR-92a-1-5p expression was assessed in SU-DHL-2 xenografts from NOD-SCID mice previously treated with vehicle (control) or OTX015 for three days <sup>1</sup>. The thick black line in each boxplot denotes the median expression. Expression of RNU6B was used for normalisation.

### Supplementary Tables Legends

**Supplementary Table S1.** Canonical pathways and hallmarks associated with OTX015-modulated miRNAs.

**Supplementary Table S2.** miRNAs with at least one BRD4-binding event within their regulatory regions and miRNAs with decreased BRD4-binding after exposure to JQ1, as determined via data mining of the ChIP-Seq datasets obtained in the ABC-DLBCL cell line HBL-1 (SRP043524) <sup>2</sup> and in the GCB-DLBCL cell line OCI-LY-1 (SRP022129) <sup>3</sup>.

**Supplementary Table S3.** Names and histological derivation of cell lines used for baseline miRNA profiling. Cell lines have already been used and described in previous studies <sup>4,5</sup>.

### References

1. Boi M, Gaudio E, Bonetti P, et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. *Clinical Cancer Research*. 2015;21(7):1628-1638.
2. Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic I $\kappa$ B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. *Proc Natl Acad Sci U S A*. 2014;111(31):11365-11370.
3. Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. *Cancer Cell*. 2013;24(6):777-790.
4. Chila R, Basana A, Lupi M, et al. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. *Oncotarget*. 2015;6(5):3394-3408.
5. Tarantelli C, Gaudio E, Arribas AJ, et al. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. *Clin Cancer Res*. 2018;24(1):120-129.